Lysine | Peptidea | PAb | BPc | In patient |
---|---|---|---|---|
20 | FK*DLGEENFK | + | + | + |
137 | K*YLYEIAR | + | + | + |
159 | HPYFYAPELLFFAK*R | + | + | + |
162 | YK*AAFTECCQAADK | + | − | − |
190 | LDELRDEGK*ASSAK | + | + | + |
195 | ASSAK*QR | + | + | + |
199 | LK*CASLQK | + | + | + |
212 | AFK*AWAVAR | + | + | + |
351 | LAK*TYETTLEK | + | + | + |
372 | VFDEFK*PLVEEPQNLIK | + | − | + |
432 | NLGK*VGSK | + | + | + |
436 | VGSK*CCK | + | − | + |
475 | VTK*CCTESLVNR | + | − | − |
525 | K*QTALVELVK | + | + | + |
541 | ATK*EQLK | + | + | + |
545 | EQLK*AVMDDFAAFVEK | + | + | + |
a *indicates modification site.
b Incubation at PA HSA molar ratio of 1:1.
c Incubation at BP HSA molar ratio of 10:1.